Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neuroblastoma 3Melanoma 2Uveal Melanoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Ganglioneuroblastoma 1Congenital Abnormalities 1Carcinoma, Renal Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × Colony-Stimulating Factors × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT01368276 2015-12-18

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

BioVex Limited

Phase 3 Completed
31 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡